Please login to the form below

Not currently logged in
Email:
Password:

renal disease

This page shows the latest renal disease news and features for those working in and with pharma, biotech and healthcare.

Price matters

Price matters

And when patients cannot pay for their kidney transplants, or the waiting list for end-stage renal disease patients is so long that they die waiting for a transplant, they have

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... However, some have warned that there could be pushback resulting from tighter reimbursement rules

  • Assisting adherence Assisting adherence

    At the same time, kidney transplantation is the treatment of choice for a growing number of patients with end-stage renal disease.

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease, an incurable inherited genetic disorder. ... greater enzyme activity after evidence of renal,

  • NICE backs expanded use of Brilique in final guidance NICE backs expanded use of Brilique in final guidance

    Patients who are at high risk of repeat cardiovascular events are often older, with evidence of multi-vessel coronary artery disease, chronic non-end-stage renal dysfunction or diabetes mellitus. ... In order to achieve this the firm is working on new

  • Keryx Biopharmaceuticals' Fexeric approved in EU Keryx Biopharmaceuticals' Fexeric approved in EU

    Keryx Biopharmaceuticals' Fexeric approved in EU. New treatment option for chronic kidney disease. ... the reach of ferric citrate to treat patients with renal disease.”. “

More from news
Approximately 1 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS

  • Deal Watch November 2015 Deal Watch November 2015

    386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease. ... Option to license. 175. Idera Pharmaceuticals. GlaxoSmithKline. Licence, collaboration. Antisence platform for selected targets in

  • The rising prevalence of diabetes in Europe The rising prevalence of diabetes in Europe

    Stroke: Risk is up to four times higher with diabetes. Cardiovascular disease: Risk is up to four times higher with diabetes. ... Diabetic nephropathy: This is the leading cause of end-stage renal disease.

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    Company acquisition. Rare disease company with marketed products in US (Chenodal to treat CTX. ... 12. 1. Co-promotion rights in US. 2. Endstage renal disease. 3.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    548. Cytori/Lorem. Vascular. Licence. Cell therapy for CVS, diabetes, and renal disease. ... 152. Calidus / Amicus. Acquisition. Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics